FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4321748475> ?p ?o ?g. }

• W4321748475 endingPage "294" @default.
• W4321748475 startingPage "287" @default.
• W4321748475 abstract "Abemaciclib [Verzenio® (USA) or Verzenios® (EU)] is a cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitor approved in combination with adjuvant endocrine therapy for patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2−), node-positive, early breast cancer with a high risk of recurrence. In a phase III trial, abemaciclib plus endocrine therapy reduced the risk of recurrence of breast cancer compared with endocrine therapy alone, including in patients who had previously received neoadjuvant chemotherapy, in patients with high- and low-scoring Ki-67 tumours, and in both premenopausal and postmenopausal patients. The tolerability profile of abemaciclib plus endocrine therapy was acceptable and manageable, with diarrhoea, infections and neutropenia being the most common adverse events. Thus, abemaciclib in combination with standard endocrine therapy is a valuable additional treatment option for patients with HR+, HER2−, node-positive early breast cancer with a high risk of recurrence. In patients with hormone receptor positive (HR+) cancers, endocrine therapy is often used to reduce the risk of breast cancer recurrence after successful initial treatment; however, in a subset of patients, recurrence rates can remain high. In a pivotal phase III trial, the addition of abemaciclib [Verzenio® (USA) or Verzenios® (EU)] to standard endocrine therapy significantly reduced the rate of breast cancer recurrence compared with endocrine therapy alone in patients with HR+, human epidermal growth factor receptor 2 negative (HER2−), node-positive early breast cancer who were at a high risk of recurrence. Benefit was seen in both patients with characteristics that are associated with higher risk (premenopausal, high Ki-67 scores, previously received neoadjuvant chemotherapy) and comparatively lower risk of recurrence (postmenopausal, low Ki-67 scores). Diarrhoea, infections and neutropenia were the most common adverse events in patients receiving abemaciclib plus endocrine therapy. The overall tolerability of abemaciclib was acceptable. The addition of abemaciclib to endocrine therapy is a valuable therapeutic option for adjuvant therapy in high-risk patients with HR+, HER2−, node-positive early breast cancer." @default.
• W4321748475 created "2023-02-25" @default.
• W4321748475 creator A5025018257 @default.
• W4321748475 creator A5032695294 @default.
• W4321748475 date "2023-02-24" @default.
• W4321748475 modified "2023-10-16" @default.
• W4321748475 title "Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence" @default.
• W4321748475 cites W1991601194 @default.
• W4321748475 cites W2023553115 @default.
• W4321748475 cites W2065392523 @default.
• W4321748475 cites W2095048284 @default.
• W4321748475 cites W2128458647 @default.
• W4321748475 cites W2168197820 @default.
• W4321748475 cites W2402797587 @default.
• W4321748475 cites W2792066790 @default.
• W4321748475 cites W3081949673 @default.
• W4321748475 cites W3083198770 @default.
• W4321748475 cites W3087561595 @default.
• W4321748475 cites W3130416374 @default.
• W4321748475 cites W3206169364 @default.
• W4321748475 cites W3210178194 @default.
• W4321748475 cites W4206349107 @default.
• W4321748475 cites W4211123279 @default.
• W4321748475 cites W4213312151 @default.
• W4321748475 cites W4220778872 @default.
• W4321748475 cites W4281560766 @default.
• W4321748475 cites W4281645436 @default.
• W4321748475 cites W4281675779 @default.
• W4321748475 cites W4308368733 @default.
• W4321748475 cites W4311018441 @default.
• W4321748475 cites W4319079877 @default.
• W4321748475 doi "https://doi.org/10.1007/s11523-023-00952-y" @default.
• W4321748475 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36826463" @default.
• W4321748475 hasPublicationYear "2023" @default.
• W4321748475 type Work @default.
• W4321748475 citedByCount "1" @default.
• W4321748475 countsByYear W43217484752023 @default.
• W4321748475 crossrefType "journal-article" @default.
• W4321748475 hasAuthorship W4321748475A5025018257 @default.
• W4321748475 hasAuthorship W4321748475A5032695294 @default.
• W4321748475 hasBestOaLocation W43217484752 @default.
• W4321748475 hasConcept C121608353 @default.
• W4321748475 hasConcept C126322002 @default.
• W4321748475 hasConcept C143998085 @default.
• W4321748475 hasConcept C197934379 @default.
• W4321748475 hasConcept C2777982462 @default.
• W4321748475 hasConcept C2778375690 @default.
• W4321748475 hasConcept C46699223 @default.
• W4321748475 hasConcept C530470458 @default.
• W4321748475 hasConcept C71315377 @default.
• W4321748475 hasConcept C71924100 @default.
• W4321748475 hasConceptScore W4321748475C121608353 @default.
• W4321748475 hasConceptScore W4321748475C126322002 @default.
• W4321748475 hasConceptScore W4321748475C143998085 @default.
• W4321748475 hasConceptScore W4321748475C197934379 @default.
• W4321748475 hasConceptScore W4321748475C2777982462 @default.
• W4321748475 hasConceptScore W4321748475C2778375690 @default.
• W4321748475 hasConceptScore W4321748475C46699223 @default.
• W4321748475 hasConceptScore W4321748475C530470458 @default.
• W4321748475 hasConceptScore W4321748475C71315377 @default.
• W4321748475 hasConceptScore W4321748475C71924100 @default.
• W4321748475 hasIssue "2" @default.
• W4321748475 hasLocation W43217484751 @default.
• W4321748475 hasLocation W43217484752 @default.
• W4321748475 hasLocation W43217484753 @default.
• W4321748475 hasOpenAccess W4321748475 @default.
• W4321748475 hasPrimaryLocation W43217484751 @default.
• W4321748475 hasRelatedWork W1990197915 @default.
• W4321748475 hasRelatedWork W2087016115 @default.
• W4321748475 hasRelatedWork W2305775430 @default.
• W4321748475 hasRelatedWork W2349164817 @default.
• W4321748475 hasRelatedWork W2427186628 @default.
• W4321748475 hasRelatedWork W2465571689 @default.
• W4321748475 hasRelatedWork W2768193050 @default.
• W4321748475 hasRelatedWork W3000123036 @default.
• W4321748475 hasRelatedWork W3191427281 @default.
• W4321748475 hasRelatedWork W4311628015 @default.
• W4321748475 hasVolume "18" @default.
• W4321748475 isParatext "false" @default.
• W4321748475 isRetracted "false" @default.
• W4321748475 workType "article" @default.